| Name | Title | Contact Details |
|---|
SimpleHealth Founded in 2018 and based in New York City, SimpleHealth makes reproductive wellness simple! Operating in 32 states and growing, SimpleHealth is a nationally recognized telehealth provider of reproductive wellness, offering birth control, herpes and cold sore treatment, and over-the-counter supplements` SimpleHealth`s mission is to be the #1 reproductive wellness provider, giving access to those who otherwise wouldn`t be able to find reproductive care in a convenient and affordable way`
Medlock Gardens Assisted Livng is a Decatur, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sunnycrest Chalet is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthLogic Systems Corporation is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.